Samphire Neuroscience Raises $5 Million Seed Round to Advance Breakthrough Neurotechnology for Women’s Health

Samphire Neuroscience, a pioneering neurotechnology company dedicated to transforming women’s health, today announces the successful closure of a $5 million seed funding round. The round was co-led by Fortify Ventures, a NY-based sector-agnostic fund backing startups shaping the future of health and work, and Inventure, a prominent Nordic early-stage investor known for backing innovative healthtech and deeptech startups, with participation from athlete-backed, sports-focused fund APEX and prior investors (SOSV, Afterwork Ventures, Firstpick Ventures, Ayuh Ventures, and Seaside Ventures, among others).

This capital infusion marks a significant milestone for the company as it continues the commercialization and further clinical development of its flagship product, NettleTM, the first Class IIa CE-certified neuromodulation device specifically designed to treat menstrual-related mental and physical symptoms.

“We’re thrilled to have the backing of such experienced investors who believe deeply in our vision and mission,” said Emilė Radytė, PhD, CEO of Samphire Neuroscience. “This funding accelerates our ability to provide safe, drug-free, and hormone-free neurotechnology to millions experiencing severe menstrual symptoms who are currently underserved by existing healthcare options.”

NettleTM is already generating significant demand, having sold out twice in its pre-launch phase across Europe and the UK and expanding to the US in 2026. Its innovative approach uses targeted transcranial brain stimulation to effectively alleviate mood and pain symptoms associated with conditions such as premenstrual dysphoric disorder (PMDD), endometriosis, and chronic pelvic pain.

Early users have praised NettleTM, describing it as ”life-changing” and ”worth every cent,” underscoring its effectiveness and ease of integration into daily routines. Independent reviews consistently highlight its positive impact on reducing anxiety, depression, and pain without side effects.

The funding will support expanded distribution, clinical partnerships, and ongoing research aimed at broadening indications and accessibility across the UK and EU, as well as expansion in the US. Samphire Neuroscience is actively working with NHS-affiliated centers and selected clinics to increase patient access.

“With this seed round, we’re not just investing in a groundbreaking product, but in a movement to redefine women’s healthcare with medical innovation,” said Dr. Radytė. “We believe neurotechnology has the power to significantly improve quality of life, providing relief for millions whose conditions have historically been overlooked or inadequately treated, like Hinge Health and Sword Health has done for MSK conditions.”

***

Read more from Samphire Neuroscience’s website.